Antipyretic TRIZ Cases

Humanizing rodent-derived anti-TSLPR antibodies reduces immunogenicity while maintaining binding affinity and therapeutic efficacy.

Linking a single-domain antigen-binding site to a Fab fragment resolves aggregation and immunogenicity while maintaining therapeutic efficacy.

Replacing natural rubber latex with anhydrous synthetic polymers prevents adhesive force degradation during long-term storage.

Neutralizing reactive oxygen species with antioxidants restores obligate anaerobe balance and reduces Ruminococcus gnavus abundance.

Embedding detectable hapten markers in polymer coatings resolves the trade-off between reliable authentication and low-cost manufacturing.

Anti-CD200 antibodies selectively bind CD200-expressing cells to reduce graft rejection without systemic side effects.

Injecting mixed mammalian connective tissue cells into intervertebral disc defects promotes regeneration and maintains disc height.

Specific mutations in helix D residues modulate immune responses for treating autoimmune diseases and cancers.

Inhibiting alpha1,3-fucosyltransferase and beta1,2-xylosyltransferase removes immunogenic residues from recombinant proteins.

A fixed-dose combination of a factor Xa inhibitor and clopidogrel eliminates INR monitoring requirements while maintaining predictable anticoagulation levels.

Acetic and lactic acid composition protects aortic endothelial mitochondria from saturated fatty acid damage.

Substituting aspartate at Kabat position 101 in the CDRH3 region of humanized anti-CD20 antibodies reduces antigen off-rates.

Calculating the activating to inhibitory Fc receptor binding ratio predicts antibody cytotoxic activity for therapeutic development.

Meglumine combined with N,N dimethylacetamide and propylene glycol dissolves hydrophobic meloxicam at room temperature without heating or EDTA.

Antibodies 37M and 37C target KIT receptor D4/D5 domains, inhibiting phosphorylation without blocking ligand binding to treat refractory cancers.

Quantifying specific microRNAs in monocytes resolves diagnostic reliability issues by providing standardized molecular markers for early disease identification.

Sigma receptor ligands modulate cellular stress responses to exert context-dependent anti-apoptotic and pro-apoptotic properties.

Ex vivo expanded IL-13+ Treg cells combined with IL-33 matrix-bound vesicles augment tissue repair capacity despite limited endogenous cell availability.

Topical surface active copolymer formulations act as oxygen reservoirs to resolve hypoxia in chronic wounds and burns.

Camelid-derived binding molecules inhibit IL-6 activity with high affinity, reducing immunogenicity without extensive antibody engineering.

Ultrasonic spraying creates tri-layer films that resolve solubility contradictions, enabling 800 µg/cm² drug loading without common solvents.

Carbohydrate-conjugated RDG dimers reduce arthritis progression while minimizing gastrointestinal toxicity.

Ethanol-water extraction of blackberry leaves yields a stable, low-odor agent that inhibits interleukin release to treat sensitive skin conditions.

A pharmaceutical composition containing miR-369-3p modulates C/EBP-β expression in dendritic cells.

Lactobacillus paracasei strains colonize the gut to restore microbiota balance disrupted by caesarean delivery and antibiotic use.

Segmenting the unique intracellular domain of ILT7 overcomes high sequence conservation to enable specific antibody binding.

Solid polymer matrix enables controlled transdermal diffusion of cannabinoids, resolving volatility and fur penetration bottlenecks.

Nucleic aptamers replace expensive heparin ligands in affinity chromatography, reducing reagent consumption while achieving therapeutic-grade Factor H purity.

Polarity-based solvent extraction isolates maca alkaloid derivatives with distinct biological activities.

IL-7 binding proteins block the IL-7/IL-7R pathway to reduce inflammation while preserving regulatory T cell function.

Alkylglycoside surfactants prevent protein aggregation during high-concentration manufacturing, eliminating cold chain storage requirements.

Characterized Lactobacillus rhamnosus pilus structures reduce pathogenic bacterial adhesion while modulating immune responses.

Sulfonyl acetamide compounds inhibit the NLRP3 inflammasome, addressing limited efficacy of existing treatments.

Immobilize heterogeneous antibodies on affinity ligands and apply enzymes to produce single glycoform samples.

Site-directed mutations in the TFPI-2 Kunitz domain enhance plasmin inhibition while reducing immunogenic reactions and anticoagulation side effects.

Segmented tridentate linkers reduce DAR distribution heterogeneity in antibody drug conjugates by enabling precise two-stage chemical coupling.

Chromatographic fractionation isolates active compounds from Plectranthus amboinicus to treat arthritis when traditional drugs fail.

Enriching native oils with fatty acid alkyl esters alters hydrolysis rates, enabling precise control over therapeutic agent release from cured coatings.

CD38-specific antibodies deplete malignant plasma cells via ADCC and CDC mechanisms, improving prognosis for multiple myeloma patients.

Inhaled cyclized peptide reduces intrapulmonary inflammation and lung injury during sepsis.

Substituting amino acid at position 44 in T cell receptor chains prevents mispairing and increases functional avidity.

Heterocyclic compounds shield the intestinal tract from chemotherapy-induced damage.

A bridging enzyme-linked immunosorbent assay detects anti-drug antibodies using simultaneous incubation of capture and tracer reagents.

Merging stimulants and antihistamines treats inflammation symptoms while reducing side effects from traditional monotherapies.

Sheet-shaped skeletal muscle cell cultures secrete myokines to enhance bioadhesiveness, resolving insufficient cell retention during intravenous administration.

Specific cyclohexyl substitutions on n-pyridinyl amides reduce drug-drug interactions while maintaining potent Pim kinase inhibition.

Optimizing MAdCAM antagonist antibody doses achieves clinical remission while minimizing side effects from broad TNF antagonists.

Measuring anti-PAD4 autoantibody levels via recombinant PAD4 binding guides mavrilimumab selection, reducing pharmaceutical waste from ineffective treatments.

Phosphine oxide alkyl amide heteroaryl compounds inhibit Tyk2 kinase to modulate IL-12, IL-23, and IFNα signaling pathways.

Subcutaneous anti-BDCA2 antibodies inhibit type I interferon production, resolving the trade-off between targeted specificity and treatment effectiveness.